Grifols, S.A. (GRFS)
Nasdaq · Healthcare · Drug Manufacturers - General
$7.41+1.37%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $5.0B
- P/E (trailing)
- 9.6
- Forward P/E
- 5.1
- Dividend yield
- 1.5%
- 52-week range
- $6.96 – $9.90
- 52-week change
- −23.93%
- EPS (trailing)
- $0.77
About Grifols, S.A.
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use.
Headquarters: Barcelona, Spain · 25,258 employees · grifols.com